RCUS
Arcus Biosciences Inc
NYSE: RCUS · HEALTHCARE · BIOTECHNOLOGY
$24.13
-2.70% today
Updated 2026-04-29
Market cap
$3.03B
P/E ratio
—
P/S ratio
12.27x
EPS (TTM)
$-3.29
Dividend yield
—
52W range
$7 – $29
Volume
1.3M
Arcus Biosciences Inc (RCUS) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $109.70M | $190.49M | $274.93M | $203.11M | $772.29M | $1.59B | $1.34B | $1.09B | $1.15B |
| Cash & equivalents | $65.16M | $98.43M | $71.06M | $57.94M | $173.41M | $147.91M | $206.00M | $127.00M | $150.00M |
| Current assets | $99.69M | $176.87M | $258.95M | $192.71M | $735.82M | $1.26B | $1.07B | $831.00M | $1.02B |
| Total liabilities | $10.24M | $36.62M | $39.98M | $39.27M | $269.99M | $750.45M | $688.00M | $633.00M | $665.00M |
| Current liabilities | $5.55M | $12.73M | $16.93M | $22.71M | $121.67M | $166.08M | $193.00M | $184.00M | $226.00M |
| Long-term debt | — | — | — | — | — | — | — | — | $48.00M |
| Shareholder equity | $99.46M | $153.87M | $234.94M | $163.84M | $502.30M | $841.45M | $657.00M | $462.00M | $485.00M |
| Retained earnings | $-20.15M | $-73.23M | $-122.83M | $-205.33M | $-328.18M | $-275.35M | $-542.00M | $-849.00M | $-1.13B |
| Accounts receivable | $405000.00 | $25000.00 | $83000.00 | $132000.00 | $1.70M | $746.82M | $43.00M | $42.00M | $25.00M |
| Inventory | — | — | — | — | $-7.17M | $-762.44M | $-172.00M | — | — |
| Goodwill | — | — | — | — | — | — | — | — | — |